Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK121-NX in Advanced Solid Tumors
NCT05627063Phase 1Active, not recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Jun 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ABSK121-NX in solid tumor, urothelial carcinoma (UC), cholangiocarcinoma (CCA) and 2 more, sponsored by Abbisko Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 4 weeks and Adverse Events at 6 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
ABSK121-NX
03
Conditions
solid tumorurothelial carcinoma (UC)cholangiocarcinoma (CCA)gastric cancer (GC)gastroesophageal junction carcinoma (GEJ)
Beyond the preview
Go deeper on NCT05627063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05627063.